Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9FMA2
|
|||
| Drug Name |
SAR442501
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Achondroplasia [ICD-11: LD24.00; ICD-10: Q77.4; ICD-9: 756.4] | Phase 1 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 3 (FGFR3) | Target Info | . | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| MicroRNAs in cancer | ||||
| Bladder cancer | ||||
| Central carbon metabolism in cancer | ||||
| Panther Pathway | FGF signaling pathway | |||
| Reactome | FGFR3 mutant receptor activation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| Bladder Cancer | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Sanofi | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.